GILEAD SCIENCES INC FDA Approval NDA 208464

NDA 208464

GILEAD SCIENCES INC

FDA Drug Application

Application #208464

Documents

Label2016-11-14
Letter2016-11-15
Label2017-04-10
Letter2017-04-12
Review2017-11-27
Letter2018-07-06
Label2019-02-05
Letter2019-02-13
Letter2020-02-05
Label2020-02-10
Letter2020-08-19
Letter2020-08-19
Label2020-08-19
Label2020-08-19
Letter2021-03-05
Label2021-03-09
Label2021-09-17
Letter2021-09-17
Letter2022-10-18
Label2022-10-19

Application Sponsors

NDA 208464GILEAD SCIENCES INC

Marketing Status

Prescription001

Application Products

001TABLET;ORALEQ 25MG BASE1VEMLIDYTENOFOVIR ALAFENAMIDE FUMARATE

FDA Submissions

TYPE 5; Type 5 - New Formulation or New ManufacturerORIG1AP2016-11-10STANDARD
EFFICACY; EfficacySUPPL4AP2018-07-03STANDARD
EFFICACY; EfficacySUPPL7AP2019-02-04STANDARD
EFFICACY; EfficacySUPPL8AP2020-02-04STANDARD
EFFICACY; EfficacySUPPL10AP2020-08-18STANDARD
EFFICACY; EfficacySUPPL11AP2020-08-18STANDARD
LABELING; LabelingSUPPL12AP2021-03-04STANDARD
LABELING; LabelingSUPPL13AP2021-09-15STANDARD
EFFICACY; EfficacySUPPL14AP2022-10-17PRIORITY

Submissions Property Types

ORIG1Null40
SUPPL4Null7
SUPPL7Null15
SUPPL8Null6
SUPPL10Null31
SUPPL11Null6
SUPPL12Null6
SUPPL13Null6
SUPPL14Null6

CDER Filings

GILEAD SCIENCES INC
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 208464
            [companyName] => GILEAD SCIENCES INC
            [docInserts] => ["",""]
            [products] => [{"drugName":"VEMLIDY","activeIngredients":"TENOFOVIR ALAFENAMIDE FUMARATE","strength":"EQ 25MG BASE","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"}]
            [labels] => [{"actionDate":"08\/18\/2020","submission":"SUPPL-11","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s010s011lbl.pdf\"}]","notes":""},{"actionDate":"08\/18\/2020","submission":"SUPPL-10","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s010s011lbl.pdf\"}]","notes":""},{"actionDate":"02\/04\/2020","submission":"SUPPL-8","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s008lbl.pdf\"}]","notes":""},{"actionDate":"02\/04\/2019","submission":"SUPPL-7","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/208464s007lbl.pdf\"}]","notes":""},{"actionDate":"04\/07\/2017","submission":"SUPPL-1","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/208464s001lbl.pdf\"}]","notes":""},{"actionDate":"11\/10\/2016","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/208464s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"11\/10\/2016","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 5 - New Formulation or New Manufacturer","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/208464s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/208464Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2016\\\/208464Orig1s000TOC.cfm\"}]","notes":">"}]
            [supplements] => [{"actionDate":"08\/18\/2020","submission":"SUPPL-11","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s010s011lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/208464Orig1s010,s011ltr.pdf\"}]","notes":">"},{"actionDate":"08\/18\/2020","submission":"SUPPL-10","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s010s011lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/208464Orig1s010,s011ltr.pdf\"}]","notes":">"},{"actionDate":"02\/04\/2020","submission":"SUPPL-8","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s008lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/208464Orig1s008ltr.pdf\"}]","notes":">"},{"actionDate":"02\/04\/2019","submission":"SUPPL-7","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/208464s007lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2019\\\/208464Orig1s007ltr.pdf\"}]","notes":">"},{"actionDate":"07\/03\/2018","submission":"SUPPL-4","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2018\\\/208464Orig1s004ltr.pdf\"}]","notes":"> Label is not available on this site."},{"actionDate":"04\/07\/2017","submission":"SUPPL-1","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/208464s001lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2017\\\/208464Orig1s001ltr.pdf\"}]","notes":">"}]
            [actionDate] => 2020-08-18
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.